Introduction
T cells of the immune system possess exquisite specificity together with powerful and diverse effector mechanisms, which makes them promising agents to use against malignant disease. Indeed, adoptive transfer of tumorspecific T cells has been demonstrated to mediate antitumor effects in a variety of mouse models. [1] [2] [3] Patients too can benefit from adoptive immunotherapy, but responses have been largely limited to a proportion of patients with melanoma. 4 Adoptively transferred T cells do not persist long term in recipients, and this has been postulated as a reason for their limited antitumor effectiveness. 5, 6 Nonmyeloablative conditioning before adoptive transfer has been demonstrated to dramatically increase the persistence of adoptively transferred T cells, and preliminary results suggest that this is associated with an increased frequency of patient responses. 7 However, this form of conditioning induces a concerning immunodeficiency and, while producing an apparent homeostatic expansion of transferred lymphocytes, does not specifically activate them.
Therefore, as an alternate approach, we have investigated the generation of dual-specific T cells as a means of providing lymphocytes with tumor specificity on the one hand, and on the other, the ability to become activated and proliferate in response to a relatively powerful immunogenic stimulus.
We have previously described the generation of dualspecific T cells that were reactive with allogeneic stimulator cells and the ovarian cancer-associated antigen, folate-binding protein (FBP). 8 These dual-specific T cells were demonstrated to respond to both FBP þ tumor cells and allogeneic splenocytes in vitro. They were also able to expand in vivo following adoptive transfer and immunization of recipient mice with allogeneic cells. However, optimal expansion required multiple injections of large numbers of allogeneic antigen-presenting cells (3 Â 10 7 ), which may be difficult to achieve when scaled up to the clinical setting.
Therefore, in this study, we investigated using reactivity against virus as the second specificity, reasoning that some viruses produce a robust immune response following a single injection of a relatively small inoculum that is easily administered. This response can result in activation and extensive proliferation of lymphocytes, and can also lead to activation of the innate immune response, through Toll-like receptor (TLR) involvement, which may often be lacking in the interaction between the endogenous immune system and tumor. The virus we used was the influenza virus, PR/8 strain (H1N1), since the response against this virus is well characterized in mice. 9 In this study, we describe the production and characterization of dual-specific T cells with reactivity against influenza virus and the tumor-associated antigen, erbB2. Specificity for erbB2 is provided by transduction of influenza virus-specific T cells with a gene encoding a chimeric receptor made up of extracellular single-chain anti-erbB2 linked to intracellular signaling molecules ( Figure 1 ). The biodistribution and persistence in vivo of dual-specific T cells was determined following adoptive transfer, together with their impact on intraperitoneal erbB2-expressing tumors.
This study serves as proof of principle that live virus can be used to directly stimulate tumor-specific T cells in vivo, and that this stimulation enables these T cells to expand and mediate antitumor activity, even in a rapidly growing tumor model. These findings may have profound implications for the design of improved immunotherapies for cancer, where a naturally robust response against foreign infectious agents might be deployed against a poorly immunogenic, often ignored, target namely tumor.
Materials and methods

Cell lines and mice
The mouse breast cancer cell line 4T1.2 was provided by Dr Robin Anderson (Peter MacCallum Cancer Centre (PMCC), Melbourne, VIC, Australia). The erbB2-expressing cell line 4T1.2-erbB2, was generated by transduction of 4T1.2 with a retroviral vector (murine stem cell vector (MSCV)) encoding the cDNA for human erbB2, and was provided by Jacob Jackson (PMCC). The mouse colon cancer cell line CT26 and the mouse kidney cancer cell line Renca were obtained from The American Type Culture Collection (ATCC, Manassas, VA, USA). Derivatives of these cell lines expressing the human tumorassociated antigen, erbB2, CT26-erbB2 and Renca-erbB2, were generated by genetic modification as for 4T1.2-erbB2. Tumor cell lines were maintained at 371C and 10% CO 2 in Dulbecco's modified Eagle's medium (DMEM) medium, supplemented with 10% heat-inactivated fetal calf serum (FCS) (Moregate Biotech, Bulimba, QLD, Australia), 2 mM glutamine (JRH Biosciences, Brooklyn, VIC, Australia), 100 U/ml penicillin and 100 mg/ml streptomycin (both from Sigma, Castle Hill, NSW, Australia).
The murine ecotropic retroviral producer cell lines GP þ E86-erbB2 and GP þ E86-FBP were generated by transfection of GP þ E86 (ATCC) with retroviral expression plasmids containing either pLXSN-scFv-a-erbB2-CD28-z, 10 or pSAMEN-scFv-a-FBP-g 8 as previously described, 11 and were maintained in RPMI 1640 medium (Gibco, Grand Island, NY, USA), supplemented with 10% FCS (Moregate), 2 mM glutamine, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, 5 Â 10 À2 mM 2ME (all from JRH), 100 U/ml penicillin and 100 mg/ml streptomycin (Sigma). Mouse T cells were cultured in supplemented RPMI, containing 50 IU/ml human recombinant interleukin-2 (rh-IL-2) (Chiron, Emeryville, CA, USA).
BALB/c and SCID mice were purchased from The Walter and Eliza Hall Institute of Medical Research (Melbourne, Australia) and housed in specific pathogenfree conditions. Mice of 6-12 weeks of age were used in all experiments, and experiments were performed according to PMCC Animal Experimental Ethics Committee guidelines.
Virus and peptides
Egg-grown A/Puerto Rico/8/34 (H1N1) influenza virus, hereafter referred to as PR/8, was used in the form of infectious allantoic fluid. 12 The infectivity of the virus stock was determined by plaque formation in MDCK cells 12 and expressed as plaque-forming units (pfu Influenza virus-specific T cells are raised in culture using viruspulsed syngeneic antigen-presenting cells (APC). During their generation, antitumor activity is conferred on them by transduction with a retroviral vector encoding a chimeric anti-erbB2 receptor. The chimeric receptor is made up of extracellular single-chain Fv (V H and V L ) of anti-erbB2 antibody, linked to transmembrane and intracellular CD28 and then to cytoplasmic domain of the z chain of the TCR-CD3 complex. A hinge region of CD8 is included in the recombinant design to enable flexibility in the receptor, and a c-myc epitope is included to enable detection of expression by flow cytometry. Therefore, a dual-specific T cell responds via its endogenous TCR against influenza virus processed and presented on MHC molecules by APC, whereas the response against tumor antigen is mediated by the chimeric receptor.
Synthetic peptides representing these epitopes were obtained (Auspep, Parkville, VIC, Australia) and were stored as 10 mg/ml stock dissolved in dimethylsulfoxide (DMSO) (Sigma) at À701C until use.
T-cell isolation and generation of dual-specific T cells Two to four weeks before use, BALB/c mice used to make dual-specific T cells were inoculated intranasally with 25-40 pfu each of PR/8 virus to increase the precursor frequency of influenza virus-specific cells. 13 Subsequently, BALB/c mouse splenocytes were isolated by dissecting a spleen, from a PR/8-primed mouse, crushing into 5 ml of hypotonic lysis buffer (pH 7. BALB/c splenocytes with the addition of either 1 Â 10 5 pfu/ml PR/8 or 1 mg/ml of influenza virus peptide, in 12-well tissue culture plates in a final volume of 1 ml. Following overnight incubation of plates at 371C/5% CO 2 , supernatant was harvested and assayed for IFN-g in duplicate wells of 96-well flat-bottom plates, using enzyme-linked immunosorbent assays (ELISA), performed according to the manufacturer's instructions (BD Pharmingen, San Diego, CA, USA).
Cytotoxicity assays
The ability of dual-specific T cells to kill tumor cells was assessed by incubating T cells with 2 Â 10 4 51
Cr-labeled target cells (in 200 ml of RPMI) at different effector to target (E:T) ratios, in triplicate wells of a 96-well roundbottomed plate incubated for 4 h at 371C/5% CO 2 . Spontaneous release of 51 Cr was determined by incubating the target cells in RPMI alone, and the maximal release was determined by adding sodium dodecyl sulfate (SDS) (Sigma) to target cells, at a 10% final concentration. Following incubation, culture supernatant was harvested using a Skatron Supernatant Collection System (Molecular Devices, Sunnyvale, CA, USA) and radioactivity measured by a Wallac Wizard automatic gamma counter (Amersham, Buckinghamshire, UK).
Proliferation:
3 H-thymidine incorporation assays The ability of dual-specific T cells to proliferate in response to both influenza virus and tumors was assessed by culturing 1 Â 10 5 T cells with either 1 Â 10 5 irradiated tumor cells, or 1 Â 10 5 virus-pulsed, irradiated autologous splenocytes, in triplicate wells of a flat-bottom 96-well plate for 48 h at 371C/10% CO 2 . Splenocytes were antigen pulsed by the addition of PR/8 to the splenocyte media for 2 h at room temperature before irradiation. Tumor cells were irradiated at 16 000-24 000 cGy, whereas splenocytes received 2000 cGy. Tritiated thymidine, 0.5 mCi/well, was added after 24 h of coculture, and cells were harvested 24 h later onto glass fiber filters (Packard, Meriden, CT, USA). Tritiated thymidine incorporation into cellular DNA was measured in a TRICARB 2100TR Liquid Scintilation Counter (Packard).
Tumor growth in mice
Groups of five SCID mice were inoculated intraperitoneally with 2 Â 10 5 Renca or Renca-erbB2 tumor cells. Some groups received 1 Â 10 6 anti-erbB2 T cells or control anti-FBP T cells by intravenous injection 24 h after tumor inoculation. After a further 24 h, some groups received intraperitoneal immunization with 1 Â 10 7 pfu PR/8 influenza virus. Tumor progression was determined by survival of mice, which was defined as 'time until mice became moribund', at which point they were euthanized.
T-cell trafficking
At various time points following CD45.1 þ T-cell transfer and immunization of CD45.2 þ SCID mice, tissues were taken and analyzed for the presence of CD45.1 þ cells by flow cytometry following staining with FITC-conjugated anti-mouse CD45.1 (Pharmingen). Spleens were crushed, and red blood cells lysed using hypotonic buffer. Tumor was dissociated by mincing with scissors and incubation for 2 h at 371C in DMEM containing hyaluronidase (100 mg/ml), collagenase (1.0 mg/ml) and DNAse (30 U/ ml) (Worthington Biochemical, Lakewood, NJ, USA). Peritoneal exudate cells were isolated by rinsing peritoneal cavities with two 5 ml aliquots of PBS and massaging. The amount of CD45.1 þ T cells in each tissue was expressed as percent of the total cell number isolated from the tissue.
Results
Dual-specific T cells respond against both tumor cells and influenza virus
Following transduction of influenza virus-reactive T cells with the chimeric anti-erbB2 receptor it was important to determine if they possessed specificity for both the virus and erbB2 þ tumor cells. This was initially done by measuring the secretion of IFN-g by T cells after coculture with various target cells. T cells transduced with either the anti-erbB2 receptor or a control receptor specific for FBP responded against influenza virus-infected syngeneic splenocytes (Figure 2a) . Antiinfluenza virus activity was also demonstrated to be polyclonal since T cells secreted IFN-g in response to several different MHC Classes I and II peptide epitopes of the influenza virus (Figure 2a ). The influenza virus-reactive T cells transduced with the antierbB2 chimeric receptor were also demonstrated to secrete IFN-g in response to erbB2 þ tumor cells, but not in response to erbB2 À tumor cells (Figure 2b ). The requirement for chimeric anti-erbB2 receptor expression for this response was apparent from the lack of activity of control anti-FBP receptor expressing T cells against erbB2 þ tumor cells.
Another important T cell function is the ability to kill appropriate target cells, which is particularly important in mediating antitumor effects. We therefore determined the ability of the dual-specific T cell population to lyse erbB2 þ tumor cells. Anti-erbB2-transduced T cells lysed a variety of erbB2 þ tumor target cells, but not erbB2 À target cells ( Figure 3 ). Lysis was mediated by the antierbB2 chimeric receptor as anti-FBP-transduced T cells were ineffective at lysing erbB2 þ cells. Thus, it was evident from these in vitro functional assays that anti-erbB2-transduced T cells could respond against erbB2
þ tumor cells and against influenza virusinfected targets, demonstrating that the T cell population had dual specificity.
Dual-specific T cells proliferate in response to influenza virus but not in response to tumor cells Central to our aim of increasing the activity and persistence of tumor-reactive T cells by incorporating influenza virus specificity is the ability of the dual-specific T cell population to expand in response to influenza virus. This was determined using a tritiated thymidine incorporation assay following exposure of T cells to tumor cells or influenza virus-pulsed target cells. Both anti-erbB2-transduced and control anti-FBP-transduced dual-specific T cells proliferated in response to stimulation with influenza virus-pulsed syngeneic splenocytes (Figure 4a) . However, the proliferative response of anti-erbB2 dualspecific T cells against tumor cells was low regardless of erbB2 antigen expression (Figure 4a) , perhaps indicating that an insufficiently strong proliferative signal was being transmitted through the chimeric receptor following encounter with tumor cells. Nevertheless, the chimeric receptor was capable of transmitting a proliferative signal because anti-erbB2 dual-specific T cells could proliferate following chimeric receptor ligation by plastic-immobilized anti-c-myc antibody, which is specific for a 10 amino acid c-myc-tag epitope incorporated into the anti-erbB2 chimeric receptor 10 ( Figure 4a ). Two potential explanations for the difference between proliferation induced by tumor cells and that induced by anti-c-myc antibody were that quantitatively greater numbers of chimeric receptor molecules were triggered through anti-c-myc, or that tumor cells secreted an inhibitory factor. To gain insight into this question antierbB2 dual-specific T cells were incubated with immobilized anti-c-myc in the presence or absence of supernatant 
Dual-specific T cells and influenza virus immunization inhibit tumor growth
Having demonstrated the ability of the dual-specific strategy to provide a proliferative signal to tumor-reactive T cells, we next wished to determine if the combination of adoptively transferred dual-specific T cells and immunization with influenza virus could impact on tumor growth in vivo. BALB/c-SCID mice were inoculated intraperitoneal with the BALB/c-derived kidney cancer lines Renca or Renca-erbB2, followed 24 h later with intravenous injection of 1 Â 10 6 dual-specific T cells. After a further 24 h, some mice were immunized intraperitoneal with 1 Â 10 7 live PR/8 influenza virus and mouse survival was determined. Renca-erbB2-bearing mice treated with anti-erbB2 dual-specific T cells alone died over a similar time frame as nontreated mice ( Figure 5 ). However, survival of mice bearing Renca-erbB2 tumors was 
Dual-specific T cells expand in vivo in response to influenza virus immunization
Although survival of tumor-bearing mice was significantly enhanced by the combination of dual-specific T cells and immunization, tumors were not eradicated, and all mice eventually succumbed to malignant disease. To gain more insight into possible limitations of the therapy, we determined the effect of influenza virus immunization on the expansion and persistence of adoptively transferred dual-specific T cells.
Tumor-bearing mice were injected intravenously with CD45.1 þ dual-specific T cells followed 24 h later by intraperitoneal immunization with influenza virus. Intraperitoneal washes and spleens were taken at intervals, and the percentage of dual-specific T cells determined by flow cytometry after staining with anti-CD45.1 monoclonal antibody. T cells first became detectable in large numbers in both intraperitoneal washes and spleen by approximately day 12 after administration of influenza virus, which then decreased to relatively low numbers by day 20 (Figures 6a and b) . The presence or absence of erbB2 antigen on tumor cells, or chimeric receptor on T cells did not impact on the extent or kinetics of T-cell expansion, because anti-erbB2 dual-specific T cells expanded in mice bearing either erbB2 þ or erbB2 À tumors, and anti-FBP dual-specific T cells expanded in tumor-bearing mice. Immunization with influenza virus was essential for expansion of dual-specific T cells, as they were undetectable in mice receiving dual-specific T cells but no immunization. Therefore, dual-specific T cells expanded in vivo to substantial numbers similar in quantity to those associated with disease resolution in other systems. 9 Thus, it seemed unlikely that insufficient numbers of cells alone was responsible for the limited antitumor effect.
Dual-specific T cells do not accumulate in large numbers in tumor
Having demonstrated substantial expansion of T cells in the spleen and intraperitoneal cavity of recipient mice, we next determined the extent of accumulation of T cells in tumor. Reasoning that maximum infiltration of tumor would likely occur when T cell numbers peaked in other Figure 5 Dual-specific T cells and immunization inhibits tumor growth in mice. BALB/c-SCID mice were injected intraperitoneal with either Renca or Renca-erbB2, followed 1 day later in some mouse groups by intravenous injection of 1 Â 10 6 T cells transduced with either anti-erbB2 or anti-FBP chimeric receptors. Some mice then received intraperitoneal injection of live influenza virus after a further 24 h. Dual-specific T cells alone or influenza virus immunization alone had no impact on mouse survival compared with nontreated (NT) mice. However, mice receiving both anti-erbB2 dual-specific T cells and influenza virus immunization survived significantly longer than all other groups of mice (P 2 ¼ 0.008, compared with nontreated, Mann-Whitney test). This experiment was performed twice times with similar results. Figure 6 Dual-specific T cells expand in vivo in response to influenza virus immunization. CD45.1 þ dual-specific T cells were transferred into congenic CD45.2 þ mice bearing tumor. Tissues were taken at intervals from groups of three mice, pooled and the percent of tissue comprising CD45.1 þ cells determined by flow cytometry. Dual-specific T cells expanded in spleen (a) and peritoneum (b), in response to influenza virus immunization. The highest number of anti-erbB2 dual-specific T cells was observed between days 12 and 14 following immunization in mice bearing Renca-erbB2 or Renca tumors. Similarly, anti-FBP dual-specific T cells expanded in mice bearing Renca-erbB2 tumors, suggesting expansion was due to the response against influenza virus, and the chimeric receptor played no role in proliferation. Immunization was required for T cell expansion, since no T cells were detected in nonimmunized T cell recipient mice. This experiment was performed twice with similar results.
Antitumor dual-specific T cells
A Murphy et al sites, we removed tumors from various groups of mice between days 12 and 14 and determined the percentage of CD45.1 þ T cells present using flow cytometry of dissociated tumor following staining with anti-CD45.1 monoclonal antibody. Surprisingly, T cells made up only a very low percentage of tumor tissue (Figure 7) , and this did not vary significantly between groups of mice bearing either erbB2 þ or erbB2 À tumors, or between groups receiving either anti-erbB2-or anti-FBP-T cells. The percent of T-cell infiltration was below that usually associated with effective responses against tumors or infection in other models.
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Discussion
Immunotherapy is a promising treatment option for cancer, and significant advances have been made using monoclonal antibodies against lymphoma, 15, 16 and cytokines against melanoma, renal cell carcinoma, leukemia and other malignancies. 17 A range of tumor antigens has also been targeted using vaccines or adoptively transferred T cells. 18 However, with the exception of melanoma, tumors have proved to be poorly immunogenic thus far. Indeed, T cells reactive with most common malignancies have been difficult to isolate.
In attempts to generate tumor reactive T cells, genetic modification techniques have been employed resulting in the generation of T cells reactive with ovarian, colon, kidney, breast and other cancers. [19] [20] [21] [22] [23] [24] [25] [26] Despite demonstrations of tumor reactivity of genetically redirected T cells, they do not expand or persist in vivo even in the continued presence of antigen. In this respect, these previously described gene-modified T cells can be considered to be poorly responsive to antigen. This may be due to the limited signaling capacity of the chimeric genes in comparison with the entire TCR-CD3 complex. Alternatively, it may be due to the non-MHC-restricted nature of antigen recognition that is often a feature of generedirected T cells, which results in T-cell encounter with antigen in the absence of optimal costimulation normally achieved in an MHC-restricted interaction with professional antigen-presenting cells.
To overcome the poor immunogenicity of tumor antigens, we and others have generated human dualspecific T cells that could respond to both tumor antigen and a strong immunogen. Immunogens used to date are alloantigen 8 in mouse cells, and Epstein-Barr (virus) EBV 27 and cytomegalovirus (CMV) 28 and influenza virus 29 in human cells. Importantly, the potential utility of dual-specific T cells was highlighted by the demonstration of tumor inhibition in mice using mouse dual-specific T cells recognizing alloantigen and the ovarian cancerassociated antigen FBP. 8 However, a potential limitation to clinical translation using this previously described system was the large doses of allogeneic cells required as immunogen. To circumvent this problem, we investigated the use of another potent immunogen as the second specificity for T cells, namely live virus. The use of live virus to stimulate dual-specific T cells in tumor-bearing mice has not been described before.
In this study, we generated dual-specific T cells that could respond to both influenza virus and the TAA erbB2. Large amounts of IFN-g were produced in response to influenza virus-pulsed splenocytes, with greater than 800 ng/ml being secreted. Reactivity against influenza virus was also demonstrated to be polyclonal since the T cell population responded to three different influenza virus-derived peptide epitopes. Reactivity was also demonstrated against a range of erbB2 þ tumor cells in vitro. The levels of IFN-g secreted in response to individual tumor types varied, with the response against Renca-erbB2 generally higher (P 2 ¼ 0.002). This did not appear to be because of differences in the level of erbB2 antigen expression as this was similar between each cell line (data not shown). Potential reasons for the different levels of IFN-g secretion include differences in expression of adhesion molecules or differential secretion of immune modulators such as TGF-b from some tumor cell lines.
Antitumor activity (40-400 ng/ml IFN-g) was appreciably less than antiviral reactivity. Nevertheless, considerable amounts of IFN-g were secreted against tumor cells, and dual-specific T cells were able to specifically lyse a range of tumor cells. The reason for the relatively lower activity of T cells against tumor is not clear, but may be due to a lower signaling capacity of the chimeric receptor compared with the endogenous TCR specific for influenza virus. It would be of interest to determine if modifications to this particular chimeric receptor composition could result in enhanced activity. For example, changes to the hinge region may result in improved function as has been demonstrated previously for some chimeric receptors. [30] [31] [32] It is not clear what proportion of the bulk T cell population were dual specific at a single cell level, although all T cells had integrated the retroviral gene encoding the chimeric receptor and neomycin phosphotransferase, since the neomycin analog G418 was used in the cell culture period. Some insight into the likely Antitumor dual-specific T cells A Murphy et al proportion of dual-specific T cells can be gained from previous studies that characterized human dual-specific T cells, which are readily cloned (in contrast to mouse T cells), where 30-40% of T cells in the bulk population were demonstrated to be reactive with two antigens following transduction with a chimeric receptor. 8 The most striking difference in T-cell response to influenza virus compared with that against tumor was seen in proliferation. T cells could proliferate in response to influenza virus but not in response to tumor cells. Potential reasons for the difference in proliferation included different levels of influenza virus antigen expression compared with TAA expression, inherent differences in signaling ability of TCR compared with chimeric receptor (despite the use of the murine CD28 endodomain), secretion of inhibitory factors by tumor cells or a combination of these reasons. However, the chimeric receptor was determined to be capable of transmitting a proliferative signal as seen by proliferation in response to chimeric receptor ligation by immobilized anti-c-myc tag antibody. A contribution from tumorderived inhibitory factors was supported by assays of T-cell function that included some tumor cell culture supernatant, which inhibited chimeric receptor-mediated proliferation.
Interestingly, all tumors may not inhibit chimeric receptor-mediated proliferation to the same degree, as suggested by the consistently lower inhibitory capacity of supernatant derived from the Renca cell lines compared with supernatants derived from other tumors (P 2 o0.01 compared with any other tumor, Mann-Whitney test, n ¼ 4). Therefore, the dual-specific approach may be of greater benefit in those cases where tumor actively inhibits T cell activity. Nevertheless, although proliferation can be mediated by the chimeric receptor, it does not approach the level possible through the endogenous TCR (Figure 4a) .
The reason for the inhibition of proliferation by tumor supernatants is not clear at this stage, but may include secretion of immune inhibitory cytokines such as TGF-b from tumor cells. It is unlikely to be due to erbB2 antigen shed from the surface of tumor cells, since similar inhibitory activity was observed using supernatant from antigen-negative tumor cells (Figure 4b) .
Although the combination of dual-specific T cells and influenza virus immunization could inhibit tumor growth in mice, tumors were not eradicated. This was despite considerable expansion of T cells as a result of immunization. Intraperitoneal injection of influenza virus results in a nonproductive infection of macrophages leading to effective presentation of viral antigens and a robust immune response, which in this case using SCID mice involved adoptively transferred T cells. Immunization resulted in extensive expansion of T cells systemically including in spleen and peritoneum. Thus, the lack of tumor response was probably not due to insufficient expansion of T cells.
The presence of inhibitory factors within tumor was a potential reason for the low impact on tumor, but T cells were demonstrated to be able to respond against tumor, at least in shorter-term assays in vitro, with both specific cytokine secretion and cytolytic activity demonstrated.
Another potential reason for the weak antitumor response included the observed poor tumor localization of T cells. Localization of T cells to tumor was less than 1%, which was much less than that usually associated with a successful response against malignancy or infectious disease. Thus, poor T-cell trafficking was seen as the most likely barrier to overcome to induce effective antitumor responses. Poor trafficking was observed despite administration of influenza virus immunogen to the same anatomical site as tumor. However, tumor tissue is unlikely to be infected with influenza virus, and may lack appropriate inflammatory or danger signals necessary for lymphocyte recruitment. Approaches involving alternate immunogens or vaccination strategies may lead to enhanced trafficking of dual-specific T cells to tumor.
Although this type of treatment did not result in complete regression of tumors in mice, it may still be of value to patients since slower disease progression in patients may afford more opportunity to impact on tumor. Renca tumor grows aggressively in mice even after administration of low numbers of tumor cells, and mice usually fail to survive beyond day 20 if untreated. However, the immunization strategy described here takes almost two weeks before expansion of large numbers of T cells is achieved, by which time tumors have progressed considerably.
Other factors to consider regarding clinical translation of this approach include the number T cells transferred, and in vitro culture period of the T cells. One million T cells was chosen as the T cell dose in these experiments as this would correspond to approximately 3 Â 10 9 human T cells when scaled up to patient treatment, which would be a reasonably achievable number of virus-specific T cells to generate from patients. In addition, the T cells used in these experiments were cultured for approximately 2 weeks to achieve sufficient numbers of G418-selected T cells. However, recent reports have demonstrated the superior antitumor activity of shorter-term cultured T cells when used in adoptive immunotherapy for melanoma in mice. 33 It will be of interest in future experiments to determine the relative impact on tumor of various numbers of T cells cultured for different periods.
The nature of the immunogen is a further consideration in the translation of this approach. A live pathogenic virus such as the PR/8 strain of influenza virus may not be appropriate in humans, and inactivated virus similar to existing vaccines may be preferred, although the extent of dual-specific T-cell expansion following this form of immunization compared with live virus is not clear. The feasibility of generating and transducing influenza-specific human T cells has been previously demonstrated. 29 Alternatively, an attenuated virus may be suitable, or a widespread persistent virus such as EBV or CMV may be an effective second specificity to use. The possibility of generating human dual-specific T cells with reactivity against tumor and EBV or CMV has been previously demonstrated in vitro. 27, 28 In this study, we attempted to circumvent the poor immunogenicity of tumors by incorporating a second response capability into tumor-specific T cells. Some impact on tumor growth was observed using this approach but the response was suboptimal. Future approaches involving strategies to enhance tumor localization of T cells, and reduce their susceptibility to tumorderived inhibitory factors, may lead to effective immunotherapies for cancer.
